New funding: Outpace Bio raised a $30 million Series A investment round to design custom cell and gene-based therapies. The science: Founded in November, the Seattle startup is developing software and hardware to manipulate how cells interact with diseases. Its initial work is focused on T cell therapies that fight solid tumors. Partnership with Lyell: The 18-person company also announced a partnership with San Francisco startup Lyell Immunopharma to pursue commercialization of a potential immune cell therapy for cancer treatment. Investors: ARTIS Ventures and Lyell led the round.